The randomized controlled period (RCP) in the phase 3 MINT trial of inebilizumab for myasthenia gravis (MG) wasn't reported ...
Switching Medicare Advantage (MA) plans is increasingly common among MA enrollees, especially those dually eligible for ...
Population Health, Equity & Outcomes is a quarterly publication dedicated to providing a platform for the exchange of research, policy analysis, and insights that aim to improve health outcomes and ...
AJMC: Your study found that emphysema affecting at least 20% of the lung on CT was consistently associated with differences ...
From a health system perspective, Martyn suggested that broader formulary access to finerenone makes sense as long as patient ...
CMS is withholding $9.8 billion in Texas Medicaid hospital funding tied to CHIRP, costing hospitals $27 million a day in a tax dispute.
John R. Hurst, MD, PhD, explains how BEAM-302 gene editing targets both lung and liver disease in alpha-1 antitrypsin ...
Patients with ≥5 impaired domains experienced markedly worse outcomes versus none, including >2-fold higher mortality and ...
Tozorakimab cut moderate/severe COPD exacerbations up to 34% in the phase 3 trials OBERON and TITANIA across smoking status ...
In addition, Godara noted that toxicity management for bispecific antibodies has evolved. While early use of these therapies ...
A separate poster, drawing on data from the National Institutes of Health's All of Us Research Program, found that women with ...
Concurrent guideline statements have increased classification ambiguity, strengthening arguments for phenotype-first ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results